Cargando…

RhoB affects colitis through modulating cell signaling and intestinal microbiome

BACKGROUND: The pathogenesis of inflammatory bowel diseases (IBD) is multifactorial, and diagnostic and treatment strategies for IBD remain to be developed. RhoB regulates multiple cell functions; however, its role in colitis is unexplored. RESULTS: Here, we found RhoB was dramatically increased in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jianming, Pei, Geng, Sun, Xuan, Xiao, Yawen, Miao, Chunhui, Zhou, Lu, Wang, Bangmao, Yang, Liu, Yu, Mingyu, Zhang, Zhi-Song, Keller, Evan T., Yao, Zhi, Wang, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482252/
https://www.ncbi.nlm.nih.gov/pubmed/36114582
http://dx.doi.org/10.1186/s40168-022-01347-3
Descripción
Sumario:BACKGROUND: The pathogenesis of inflammatory bowel diseases (IBD) is multifactorial, and diagnostic and treatment strategies for IBD remain to be developed. RhoB regulates multiple cell functions; however, its role in colitis is unexplored. RESULTS: Here, we found RhoB was dramatically increased in colon tissues of ulcerative colitis (UC) patients and mice with DSS-induced colitis. Compared with wild type mice, RhoB(+/−) and RhoB(−/−) mice developed milder DSS-induced colitis and increased goblet cell numbers and IEC proliferation. Decreased RhoB promoted goblet cell differentiation and epithelial regeneration through inhibiting Wnt signaling pathway and activating p38 MAPK signaling pathway. Moreover, increased SCFA-producing bacteria and SCFA concentrations were detected in intestinal microbiome of both RhoB(+/−) and RhoB(−/−) mice and upregulated SCFA receptor expression was also observed. CONCLUSIONS: Taken together, a higher level of RhoB is associated with UC, which also contributes to UC development through modulating cell signaling and altering intestinal bacterial composition and metabolites. These observations suggest that RhoB has potential as a biomarker and a treatment target for UC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01347-3.